Cargando…

How Do Patients Who Fail First-Line TB Treatment but Who Are Not Placed on an MDR-TB Regimen Fare in South India?

SETTING: Seven districts in Andhra Pradesh, South India OBJECTIVES: To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns...

Descripción completa

Detalles Bibliográficos
Autores principales: Burugina Nagaraja, Sharath, Satyanarayana, Srinath, Chadha, Sarabjit Singh, Kalemane, Santosha, Jaju, Jyoti, Achanta, Shanta, Reddy, Kishore, Potharaju, Vishnu, Motta Shamrao, Srinivas Rao, Dewan, Puneet, Rony, Zachariah, Tetali, Shailaja, Anchala, Raghupathi, Kannuri, Nanda Kishore, Harries, Anthony David, Kuldeep Singh, Sachdeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191158/
https://www.ncbi.nlm.nih.gov/pubmed/22022433
http://dx.doi.org/10.1371/journal.pone.0025698
Descripción
Sumario:SETTING: Seven districts in Andhra Pradesh, South India OBJECTIVES: To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST). DESIGN: Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009. RESULTS: There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success. CONCLUSION: Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed.